Pembrolizumab + Focused Ultrasound for Glioblastoma

This trial tests a new approach for treating recurring glioblastoma, a type of brain cancer. It combines pembrolizumab with Navifus Focused Ultrasound Sonification, which uses sound waves to target the tumor. Researchers aim to determine the safety and effectiveness of this combination against the cancer. Individuals whose glioblastoma has returned after surgery and standard treatments, and who have a specific type of tumor with mismatch repair deficiency, may qualify for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial requires that you stop taking any immune checkpoint inhibitors, other investigational agents, or live vaccines at least 14 days before starting the trial. You also need to stop any systemic anti-cancer therapies at least 28 days before the trial and avoid high-dose systemic corticosteroids within 5 days before starting the trial.

Research shows that previous studies have found pembrolizumab to be generally well-tolerated by patients. The FDA has already approved it for other conditions, suggesting reasonable safety. Studies have shown that focused ultrasound is safe and tolerable for patients with glioblastoma. Specifically, one study found that NaviFUS treatment, a type of focused ultrasound, was safe and tolerable for all patients involved, with no reports of severe side effects. Although this trial is in the early stages, these findings offer some reassurance about the safety of both treatments.¹²³⁴⁵

Researchers are excited about the combination of Pembrolizumab and focused ultrasound for glioblastoma because it offers a novel approach to tackling this aggressive brain cancer. Unlike standard treatments like surgery, radiation, and chemotherapy, this approach uses Pembrolizumab, an immunotherapy drug, to harness the body's immune system to fight cancer. The focused ultrasound enhances the delivery and effectiveness of Pembrolizumab by temporarily opening the blood-brain barrier, potentially allowing more of the drug to reach the tumor. This combination aims to improve treatment effectiveness and might provide a new avenue for those with recurrent glioblastoma, offering hope for better outcomes.

This trial will investigate the combination of pembrolizumab with focused ultrasound sonication for treating glioblastoma. Research has shown that this combination might help treat glioblastoma by boosting the body's immune response. Focused ultrasound has shown promise in extending the lives of glioblastoma patients. Specifically, in some studies, patients who received focused ultrasound with chemotherapy lived almost 40% longer than those who only had chemotherapy. This ultrasound method might also safely open the blood-brain barrier, potentially allowing pembrolizumab to reach and attack tumor cells more effectively. These findings suggest that this combination could be a promising approach for treating this aggressive brain cancer.¹⁶⁷⁸⁹